PAXIL CR

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
PAXIL CR
Generic name
PAROXETINE HYDROCHLORIDE
Manufacturer
Apotex Corp
Product type
HUMAN PRESCRIPTION DRUG
SPL set ID
483bd97f-c4d0-4e23-aaa8-6334f4471e0c
SPL ID
537a5f05-8311-a97e-acde-275206595dcd
Version
34
Effective date
2026-09-30
Source export date
2026-11-13
Source partition
7
Source file
https://download.open.fda.gov/drug/label/drug-label-0007-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/875ce92e4370b2000cf566c8a9c0e4d02cceccd3a3b18a8b0b87928b28506f0b/drug-label-0007-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 16:34:49
Harmonized routes table
Harmonized routes
ORAL

Boxed warning cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Boxed warning sections page 1 of 1 · 1 matching rows.

boxed warning

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [See Warnings and Precautions ( 5.1 )] PAXIL CR is not approved for use in pediatric patients [see Use in Specific Populations ( 8.4 )]. WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. Antidepressants increase the risk of suicidal thoughts and behavior in pediatric and young adult patients ( 5.1 ). Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors ( 5.1 ). PAXIL CR is not approved for use in pediatric patients. ( 5.1 , 8.4)

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 2 matching rows.

warnings and cautions

5 WARNINGS AND PRECAUTIONS Serotonin Syndrome: Monitor all patients taking PAXIL CR for the emergence of serotonin syndrome. If occurs, discontinue PAXIL CR and serotonergic agents and initiate supportive measures. ( 5.2 ) Embryofetal Toxicity: For women who intend to become pregnant or who are in their first trimester of pregnancy, PAXIL CR, should be initiated only after consideration of the other available treatment options ( 5.4 , 8.1 ) Increased Risk of Bleeding: For patients taking warfarin, carefully monitor the international normalized ratio when initiating, titrating, or discontinuing PAXIL CR ( 5.5 ) Seizures : Use with caution in patients with seizure disorders and PAXIL CR should be discontinued in patients who develop a seizure. ( 5.8 ) Angle-Closure Glaucoma: Avoid use of PAXIL CR in patients with untreated anatomically narrow angles. (5.9 ) Hyponatremia: In patients with symptomatic hyponatremia, discontinue PAXIL CR and institute appropriate medical intervention ( 5.10 ) Sexual Dysfunction: Inquire about sexual function prior to initiation of PAXIL CR and to inquire specifically about changes in sexual function during PAXIL CR treatment ( 1 ) 5.1 Suicidal Thoughts and Behaviors in Pediatric and Young Adult Patients In pooled analyses of placebo-controlled trials of antidepressant drugs (SSRIs and other antidepressant classes) that included approximately 77,000 adult patients and 4,500 pediatric patients, the incidence of suicidal thoughts and behaviors in antidepressant-treated patients age 24 years and younger was greater than in placebo-treated patients. There were differences in absolute risk of suicidal thoughts and behaviors across the different uses, with the highest incidence in patients with MDD. The drug-placebo differences in the number of cases of suicidal thoughts and behaviors per 1,000 patients treated are provided in Table 2. Table 2: Risk Differences of the Number of Patients with Suicidal Thoughts and Behaviors in the Pooled Placebo-Controlled Trials of Antidepressants in Pediatric 1 and Adult Patients Age Range Drug-Placebo Difference in Number of Patients of Suicidal Thoughts and Behaviors per 1,000 Patients Treated I ncreases Compared to Placebo <18 years old 14 additional patients 18-24 years old 5 additional patients Decreases Compared to Placebo 25-64 years old 1 fewer patient ≥65 years old 6 fewer patients 1 PAXIL CR is not approved for use in pediatric patients. It is unknown whether the risk of suicidal thoughts and behaviors in pediatric patients and young adults extends to longer-term use, i.e., beyond four months. However, there is substantial evidence from placebo-controlled maintenance trials in adults with MDD that antidepressants delay the recurrence of depression and that depression itself is a risk factor for suicidal thoughts and behaviors. Monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of drug therapy, and at times of dosage changes. Counsel family members or caregivers of patients to monitor for changes in behavior and to alert the health care provider. Consider changing the therapeutic regimen, including possibly discontinuing PAXIL CR, in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors. 5.2 Serotonin Syndrome Selective serotonin reuptake inhibitors SSRIs, including PAXIL CR, can precipitate serotonin syndrome, a potentially life-threatening condition. The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. John's Wort) and with drugs that impair metabolism of serotonin, i.e., MAOIs [see Contraindications ( 4 ), Drug Interactions ( 7.1 )]. Serotonin syndrome can also occur when PAXUIL CR is used alone. Serotonin syndrome signs and symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). The concomitant use of PAXIL CR with MAOIs is contraindicated. In addition, do not initiate PAXIL CR in a patient being treated with MAOIs such as linezolid or intravenous methylene blue. No reports involved the administration of methylene blue by other routes of administration (such as orally or local tissue injection). If it is necessary to initiate treatment with an MAOI such as linezolid or intravenous methylene blue in a patient taking PAXIL CR, discontinue PAXIL CR before initiating treatment with the MAOI [see Contraindications ( 4 ), and Drug Interactions (7.1) ]. Monitor all patients taking PAXIL CR for the emergence of serotonin syndrome. Discontinue treatment with PAXIL CR and any concomitant serotonergic drug immediately if the above symptoms occur, and initiate supportive symptomatic treatment. If concomitant use of PAXIL CR with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. 5.3 Drug Interactions Leading to QTc Interval Prolongation Cases of QTc interval prolongation have been reported with the use of paroxetine, although a causal relationship with PAXIL CR has not been established. PAXIL CR is a CYP2D6 inhibitor. Concomitant use of PAXIL CR with CYP2D6 substrates that prolong the QTc interval can increase the concentration of those CYP2D6 substrates and may result in a greater increase in the QTc interval and adverse reactions associated with QTc interval prolongation, including Torsade de pointes, other serious arrythmias, and sudden death. The concomitant use of PAXIL CR is contraindicated with CYP2D6 substrates that prolong the QTc interval [see Drug Interactions ( 7 ) and Clinical Pharmacology ( 12.3 )]. 5.4 Embryofetal Toxicity PAXIL CR can cause fetal harm when administered to a pregnant woman. Based on meta-analyses of epidemiological studies, exposure to paroxetine in the first trimester of pregnancy is associated with a less than 2-fold increase in the rate of cardiovascular malformations among infants. For women who intend to become pregnant or who are in their first trimester of pregnancy, PAXIL CR, should be initiated only after consideration of the other available treatment options [see Use in Specific Populations ( 8.1 )]. 5.5 Increased Risk of Bleeding Drugs that interfere with serotonin reuptake inhibition, including PAXIL CR, increase the risk of bleeding events. Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDS), other antiplatelet drugs, warfarin, and other anticoagulants may add to this risk. Case reports and epidemiological studies (case‑control and cohort design) have demonstrated an association between use of drugs that interfere with serotonin reuptake and the occurrence of gastrointestinal bleeding. Based on data from the published observational studies, exposure to SSRIs, particularly in the month before delivery, has been associated with a less than 2-fold increase in the risk of postpartum hemorrhage [see Use in Specific Populations ( 8.1 )] . Bleeding events related to drugs that interfere with serotonin reuptake have ranged from ecchymoses, hematomas, epistaxis, and petechiae to life-threatening hemorrhages. Inform patients about the increased risk of bleeding associated with the concomitant use of PAXIL CR and antiplatelet agents or anticoagulants. For patients taking warfarin, carefully monitor the international normalized ratio when initiating, titrating, or discontinuing PAXIL CR. 5.6 Activation of Mania or Hypomania In patients with bipolar disorder, treating a depressive episode with PAXIL CR or another antidepressant may precipitate a mixed/manic episode. During controlled clinical trials of immediate‑release paroxetine tablets for unipolar depression, hypomania or mania occurred in approximately 1% of immediate-release paroxetine tablets‑treated patients compared to 1.1% of active‑control-treated patients and 0.3% of placebo‑treated patients. Prior to initiating treatment with PAXIL CR, screen patients for any personal or family history of bipolar disorder, mania, or hypomania. 5.7 Discontinuation Syndrome Adverse reactions after discontinuation of serotonergic antidepressants, particularly after abrupt discontinuation, included nausea, sweating, dysphoric mood, irritability, agitation, dizziness, sensory disturbances (e.g., paresthesia, such as electric shock sensations), tremor, anxiety, confusion, headache, lethargy, emotional lability, insomnia, hypomania, tinnitus, and seizures. When discontinuing PAXIL CR, a gradual reduction in dosage rather than abrupt cessation is recommended whenever possible [see Dosage and Administration ( 2.7 )]. Adverse reactions have been reported upon discontinuation of paroxetine treatment in pediatric patients. The safety and effectiveness of PAXIL CR in pediatric patients have not been established [see Warnings and Precautions ( 5.1 ) and Use in Specific Populations ( 8.4 )]. 5.8 Seizures PAXIL CR has not been systematically evaluated in patients with seizure disorders. Patients with history of seizures were excluded from clinical studies. During clinical studies with immediate-release paroxetine, seizures occurred in 0.1% of patients treated with immediate-release paroxetine. PAXIL CR should be prescribed with caution in patients with a seizure disorder. Discontinue PAXIL CR in patients who develop a seizure. 5.9 Angle-Closure Glaucoma The pupillary dilation that occurs following use of many antidepressant drugs including PAXIL CR may trigger an angle closure attack in a patient with anatomically narrow angles who does not have a patent iridectomy. Cases of angle-closure glaucoma associated with use of immediate-release paroxetine have been reported. Avoid use of antidepressants, including PAXIL CR, in patients with untreated anatomically narrow angles. 5.10 Hyponatremia Hyponatremia may occur as a result of treatment with SSRIs, including PAXIL CR. Cases with serum sodium lower than 110 mmol/L have been reported. Signs and symptoms of hyponatremia include headache, difficulty concentrating, memory impairment, confusion, weakness, and unsteadiness, which may lead to falls. Signs and symptoms associated with more severe and/or acute hyponatremia cases have included hallucination, syncope, seizure, coma, respiratory arrest, and death. In many cases, this hyponatremia appears to be the result of the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs. [see Use in Specific Populations ( 8.5 )]. In patients with symptomatic hyponatremia, discontinue PAXIL CR and institute appropriate medical intervention. 5.11 Sexual Dysfunction Use of SSRIs, including PAXIL CR, may cause symptoms of sexual dysfunction [see Adverse Reactions ( 6.1 )]. In male patients, SSRI use may result in ejaculatory delay or failure, decreased libido, and erectile dysfunction. In female patients, SSRI use may result in decreased libido and delayed or absent orgasm. Recommend prescribers inquire about sexual function prior to initiation of PAXIL CR and to inquire specifically about changes in sexual function during PAXIL CR treatment because sexual function may not be spontaneously reported. When evaluating changes in sexual function, obtain a detailed history (including timing of symptom onset) because sexual symptoms may have other causes, including the underlying psychiatric disorder. Discuss potential management strategies to support patients in making informed decisions about treatment for sexual dysfunction. 5.12 Reduction of Efficacy of Tamoxifen Some studies have shown that the efficacy of tamoxifen, as measured by breast cancer relapse and mortality, may be reduced with concomitant use of paroxetine as a result of paroxetine’s irreversible CYP2D6 inhibition and lower concentration of the active metabolite of tamoxifen [see Drug Interactions ( 7.1 )]. One study suggested that the risk may increase with longer duration of concomitant use of paroxetine and tamoxifen. However, other studies have failed to demonstrate such a risk. When tamoxifen is used for the treatment or prevention of breast cancer, prescribers should consider using an alternative antidepressant with little or no CYP2D6 inhibition rather than PAXIL CR. 5.13 Fracture Risk Epidemiological studies on fracture risk during exposure to some antidepressant drugs, including SSRIs, have reported an association between antidepressant drug treatment and fractures. There are multiple possible causes for this association, and it is unknown to what extent fracture risk is directly attributable to SSRI treatment.

warnings and cautions table

<table> <caption/> <col width="13%"/> <col width="82%"/> <tbody> <tr> <td align="center" styleCode="Rrule Botrule Lrule Toprule" valign="top"> <paragraph> <content styleCode="bold">Age Range</content> </paragraph> </td> <td align="center" styleCode="Rrule Botrule Toprule" valign="top"> <paragraph> <content styleCode="bold">Drug-Placebo Difference in Number of Patients of Suicidal Thoughts and Behaviors per 1,000 Patients Treated</content> </paragraph> </td> </tr> <tr> <td align="center" colspan="2" styleCode="Rrule Lrule Botrule" valign="top"> <paragraph>I<content styleCode="bold">ncreases Compared to Placebo</content> </paragraph> </td> </tr> <tr> <td align="center" styleCode="Rrule Lrule Botrule" valign="top"> <paragraph>&lt;18 years old</paragraph> </td> <td align="center" styleCode="Rrule Botrule" valign="top"> <paragraph>14 additional patients</paragraph> </td> </tr> <tr> <td align="center" styleCode="Rrule Lrule Botrule" valign="top"> <paragraph>18-24 years old</paragraph> </td> <td align="center" styleCode="Rrule Botrule" valign="top"> <paragraph>5 additional patients</paragraph> </td> </tr> <tr> <td align="center" colspan="2" styleCode="Rrule Lrule Botrule" valign="top"> <paragraph> <content styleCode="bold">Decreases Compared to Placebo</content> </paragraph> </td> </tr> <tr> <td align="center" styleCode="Rrule Lrule Botrule" valign="top"> <paragraph>25-64 years old</paragraph> </td> <td align="center" styleCode="Rrule Botrule" valign="top"> <paragraph>1 fewer patient</paragraph> </td> </tr> <tr> <td align="center" styleCode="Rrule Botrule Lrule" valign="top"> <paragraph>&#x2265;65 years old</paragraph> </td> <td align="center" styleCode="Rrule Botrule" valign="top"> <paragraph>6 fewer patients</paragraph> </td> </tr> </tbody> </table>

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 4 matching rows.

adverse reactions

6 ADVERSE REACTIONS The following adverse reactions are included in more detail in other sections of the prescribing information: Suicidal thoughts and behaviors [see Warnings and Precautions ( 5.1 )] Serotonin syndrome [see Warnings and Precautions ( 5.2 )] Increased risk of bleeding [see Warnings and Precautions ( 5.5 )] Activation of mania/hypomania [see Warnings and Precautions ( 5.6 )] Discontinuation syndrome [see Warnings and Precautions ( 5.7 )] Seizures [see Warnings and Precautions ( 5.8 )] Angle-closure glaucoma [see Warnings and Precautions ( 5.9 )] Hyponatremia [see Warnings and Precautions ( 5.10 )] Sexual dysfunction [see Warnings and Precautions ( 5.11 )] Risk of fracture [see Warnings and Precautions ( 5.12 )] Most common adverse reactions (≥5% and at least twice placebo) in placebo-controlled MDD, PD, SAD, and PMDD clinical trials: abnormal ejaculation, abnormal vision, asthenia, constipation, decreased appetite, diarrhea, dizziness, dry mouth, female genital disorder, impotence, insomnia, libido decreased, nausea, somnolence, sweating, tremor. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Apotex Corp.at 1-800-706-5575 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Safety data for PAXIL CR are from 11 short-term, placebo‑controlled clinical trials including 3 studies in patients with major depressive disorder (MDD) (Studies 1, 2, and 3), 3 studies in patients with panic disorder (PD) (Studies 4, 5, and 6), 1 study in patients with social anxiety disorder (SAD) (Study 7), and 4 studies in female patients with premenstrual dysphoric disorder (PMDD) (Studies 8, 9, 10, and 11) [see Clinical Studies ( 14 )] . These 11 trials included 1,627 patients treated with PAXIL CR. Studies 1 and 2 were 12-week studies that enrolled patients 18 to 65 years old with MDD. Patients in the PAXIL CR group received PAXIL CR at a dosage that ranged from 25 mg to 62.5 mg once daily. Study 3 was a 12-week study in patients 60 to 88 years old with MDD. Patients in the PAXIL CR group received PAXIL CR at a dosage that ranged from 12.5 mg to 50 mg once daily. Studies 4, 5, and 6 were 10-week studies in patients 19 to 72 years old with PD. Patients in the PAXIL CR group received PAXIL CR at a dosage that ranged from 12.5 mg to 75 mg once daily. Study 7 was a 12-week study that enrolled adult patients. Patients in the PAXIL CR group received PAXIL CR with SAD at a dosage that ranged from 12.5 mg to 37.5 mg once daily. Studies 8, 9, and 10 were 12‑week, placebo‑controlled trials in female patients 18 to 46 years old with PMDD. Patients in the PAXIL CR group received PAXIL CR at a dosage of 12.5 mg or 25 mg once daily. Study 11 was a 12-week placebo‑controlled trial in patients 18 to 46 years old with PMDD. Patients in the PAXIL CR group received PAXIL CR two weeks prior to the onset of each menses (luteal phase dosing) at a dosage of 12.5 mg or 25 mg once daily. Adverse Reactions that Led to Discontinuation in Patients with MDD, PD, SAD, and PMDD In pooled studies in patients with MDD, PD and SAD, the most common adverse reactions that led to study withdrawal in the PAXIL CR-treated patients were nausea (up to 4% of patients), asthenia, headache, depression, insomnia, and abnormal liver function tests (each occurred in up to 2% of patients), and dizziness, somnolence, and diarrhea (each occurred up to 1% of patients). In pooled studies for PMDD, the most common adverse reactions that lead to study withdrawal in the PAXIL CR-treated patients were nausea (occurred in up to 6% of patients), asthenia (occurred in up to 5% of patients), somnolence (occurred in up to 4% of patients), insomnia (occurred in approximately 2% of patients); and impaired concentration, dry mouth, dizziness, decreased appetite, sweating, tremor, yawn and diarrhea (occurred in less than or equal to 2% of patients). Common Adverse Reactions in MDD, PD, and SAD TTable 3 presents the most common adverse reactions (incidence ≥5% in PAXIL CR-treated patients and greater than in placebo-treated within at least one of the patient populations) in controlled trials in patients with MDD, PD, and SAD. Table 3. Most Common Adverse Reactions 1 in 10 to 12 Week Studies of MDD, PD, and SAD MDD 18 to 65 year olds MDD ≥60 years old Panic Disorder Social Anxiety Disorder PAXIL CR (N=212) % Placebo (N=211) % PAXIL CR (N=104) % Placebo (N=109) % PAXIL CR (N=444) % Placebo (N=445) % PAXIL CR (N=186) % Placebo (N=184) % Headache 27 20 17 13 NA NA 23 17 Abnormal Ejaculation b,c 26 1 17 3 27 3 15 1 Somnolence 22 8 21 12 20 9 9 4 Nausea 22 10 - - 23 17 22 6 Diarrhea 18 7 15 9 12 9 9 8 Insomnia 17 9 10 8 20 11 9 4 Dry Mouth 15 8 18 7 13 9 3 2 Dizziness 14 4 9 5 NA NA 7 4 Asthenia 14 9 15 14 15 10 18 7 Female Genital Disorder b,d 10 < 1 - - 7 1 3 0 Constipation 10 4 13 5 9 6 5 2 Tremor 7 1 7 0 8 2 4 2 Abdominal Pain 7 4 - - 6 4 5 4 Libido Decreased 7 3 8 <1 9 4 1 Sweating 6 2 10 <1 7 2 14 3 Flatulence 6 4 - - NA NA NA NA Abnormal Vision a 5 1 - - 3 10 1 9 Impotence b 5 3 9 3 10 1 9 0 Back Pain 5 3 - - NA NA 4 1 Decreased Appetite 2 12 5 8 6 1 <1 Dyspepsia NA NA 13 10 NA NA 2 <1 Myalgia NA NA - - 5 3 NA NA Sinusitis NA NA - - 8 5 NA NA Nervousness NA NA - - 8 7 NA NA Anxiety NA NA - - 5 4 2 1 Yawn 0 - - 3 0 2 0 1 ≥ 5% of patients treated with PAXIL CR and greater than in patients treated with placebo. Hyphen = the reaction listed occurred in <5% of patients treated with PAXIL CR NA = the adverse reaction listed did not occur in this group of patients a Mostly blurred vision b Based on the number of males or females c Mostly anorgasmia or delayed ejaculation d Mostly anorgasmia or delayed orgasm Other Adverse Reactions Observed in Studies of MDD, PD, and SAD Adverse reactions from studies in MDD (not including Study 3 in patients 60 years of age and older), PD, and SAD that occurred in 1% to 5% of PAXIL CR-treated patients and at an incidence greater than in placebo-treated patients included allergic reaction, tachycardia, vasodilatation, hypertension, migraine, vomiting, weight loss, weight gain, hypertonia, paresthesia, agitation, confusion, myoclonus, concentration impaired, depression, rhinitis, cough increased, bronchitis, photosensitivity, eczema, taste perversion, UTI, menstrual disorder, urinary frequency, urination impaired, and vaginitis. Adverse Reactions in Patients with PMDD Table 4 displays common adverse reactions (incidence of 5% or more and greater in PAXIL CR-treated patients and greater than placebo-treated patients within at least one of the studies) in female patients with PMDD (Studies 8, 9, 10, and 11). The following adverse reactions in the PMDD studies with continuous dosing (Studies 8, 9, and 10 were dose-related: nausea, somnolence, sweating, dry mouth, dizziness, decreased appetite, tremor, impaired concentration, yawn, paresthesia, hyperkinesia, and vaginitis. Table 4. Common Adverse Reactions 1 in Pooled Studies in Female Patients with PMDD (Studies 8, 9, 11), and in Study 10 a,b,c % Reporting Adverse Reaction Continuous Dosing Luteal Phase Dosing PAXIL CR (n = 681) Placebo (n = 349) PAXIL CR (n = 246) Placebo (n = 120) Asthenia 17% 6% 15% 4% Nausea 17% 7% 18% 2% Headache 15% 12% NA NA Libido Decreased 12% 5% 9% 6% Somnolence 9% 2% 3% <1% Female Genital Disorders c 8% 1% 2% 0% Insomnia 8% 2% 7% 3% Sweating 7% <1% 6% <1% Dizziness 7% 3% 6% 3% Diarrhea 6% 2% 6% 3% Infection 6% 4% NA NA Constipation 5% 1% 2% <1% Tremor 4% <1% 5% 0% 1 ≥5% of patients treated with PAXIL CR and greater than in placebo-treated patients. NA= the adverse reaction information is not available in this population. a <1% means greater than zero and less than 1%. b The luteal phase and continuous dosing PMDD trials were not designed for making direct comparisons between the two dosing regimens. c Mostly anorgasmia or difficulty achieving orgasm. Male and Female Sexual Dysfunction The percentage of patients who reported symptoms of sexual dysfunction in patients with MDD, PD, SAD, and PMDD (Studies 1, 2, 4, 5, 6, 7, 8, 9, 10, and 11) are presented in Table 5. Reliable estimates of the incidence and severity of untoward experiences involving sexual desire, performance, and satisfaction are difficult to obtain, in part because patients and healthcare providers may be reluctant to discuss them. Accordingly, estimates of the incidence of untoward sexual experience and performance cited in labeling may underestimate their actual incidence. Paroxetine treatment has been associated with several cases of priapism. In those cases with a known outcome, patients recovered without sequelae. Table 5. Adverse Reactions Related to Sexual Dysfunction in Pooled 10-12 Week Studies of MDD, PD, SAD, and PMDD Studies 1 and 2 (MDD) Studies 4, 5 and 6 (PD) Study 7 (SAD) Studies 8, and 9 and 10 (Continuous Dosing) (PMDD) Study 11 (Luteal Phase Dosing) (PMDD) PAXIL CR Placebo PAXIL CR Placebo PAXIL CR Placebo PAXIL CR Placebo PAXIL CR Placebo n (males) 78 78 162 194 88 97 NA NA NA NA Abnormal ejaculation 26% 1% 27 27% 3% 15% 1% NA NA NA Decreased Libido 10% 5% 9% 6% 13% 1% NA NA NA NA Impotence 5% 3% 10% 1% 9% 0% NA NA NA NA n (females) 134 133 282 251 98 87 681 349 246 120 Orgasmic Disturbance 10% <1% 7% 1% 3% 0% 8% 1% 2% 0% Decreased Libido 4% 2% 8% 2% 4% 1% 12% 5% 9% 6% NA = male patients were not included in these studies. Less Common Adverse Reactions The following adverse reactions occurred during the clinical studies of PAXIL CR and are not included elsewhere in the labeling. Reactions are categorized by body system and listed in order of decreasing frequency according to the following definitions: Frequent adverse reactions are those that occurred on 1 or more occasions in at least 1/100 patients; infrequent adverse reactions are those that occurred in 1/100 to 1/1,000 patients; rare reactions are those that occurred in fewer than 1/1,000 patients. Cardiovascular System: Infrequent was postural hypotension. Hemic and Lymphatic System: Rare was thrombocytopenia. Metabolic and Nutritional Disorders: Infrequent were generalized edema and hypercholesteremia. Nervous System: Infrequent were convulsion, akathisia, and manic reaction. Psychiatric: Infrequent were hallucinations. Skin and Appendages: Frequent was rash; infrequent was urticaria; rare was angioedema and erythema multiforme. Urogenital System: Infrequent was urinary retention; rare was urinary incontinence. 6.2 Postmarketing Experience The following reactions have been identified during post approval use of paroxetine. Because these reactions are reported voluntarily from a population of unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Blood disorders: events related to impaired hematopoiesis (including agranulocytosis, aplastic anemia, bone marrow aplasia and pancytopenia), haemolytic anaemia Cardiac disorders: torsade de pointes, ventricular fibrillation, ventricular tachycardia Endocrine disorders: hyperprolactinemia, syndrome of inappropriate antidiuretic hormone (SIADH) secretion Gastrointestinal disorders: acute pancreatitis Hepatobiliary disorders: elevated liver function tests (the most severe cases were deaths due to liver necrosis, and grossly elevated transaminases associated with severe liver dysfunction) Immune system disorders : anaphylactic reaction, vasculitis syndromes (such as Henoch-Schönlein purpura). Metabolism and nutrition disorders : porphyria Musculoskeletal and connective tissue disorders : hypertonia Nervous system disorders : extrapyramidal symptoms (i.e. akathisia, bradykinesia, cogwheel rigidity, dystonia, trismus), Guillain-Barré Syndrome, anosmia, hyposmia, optic neuritis, restless legs syndrome (RLS), status epilepticus Pregnancy, puerperium and perinatal conditions: eclampsia, premature birth Renal and urinary disorders : acute renal failure Reproductive system and breast disorders : galactorrhea, priapism Respiratory, thoracic and mediastinal disorders : allergic alveolitis, laryngospasm, pulmonary hypertension Skin and subcutaneous tissue disorders : Drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS), Toxic epidermal necrolysis (TEN) Vascular disorders : severe hypotension

adverse reactions table

<table frame="box" rules="all"> <tbody align="center"> <tr> <td> <content styleCode="bold"> </content> </td> <td colspan="2"> <content styleCode="bold">MDD</content> <content styleCode="bold"> 18 to 65 year olds</content> </td> <td colspan="2"> <content styleCode="bold">MDD</content> <content styleCode="bold">&#x2265;60 years old </content> </td> <td colspan="2"> <content styleCode="bold">Panic Disorder</content> </td> <td colspan="2"> <content styleCode="bold">Social Anxiety Disorder</content> </td> </tr> <tr> <td/> <td> PAXIL CR (N=212) %</td> <td> Placebo (N=211) %</td> <td> PAXIL CR (N=104) %</td> <td> Placebo (N=109) %</td> <td> PAXIL CR (N=444) %</td> <td> Placebo (N=445) %</td> <td> PAXIL CR (N=186) %</td> <td> Placebo (N=184) %</td> </tr> <tr> <td align="left"> Headache </td> <td> 27</td> <td> 20</td> <td> 17 </td> <td> 13 </td> <td> NA </td> <td> NA </td> <td> 23 </td> <td> 17 </td> </tr> <tr> <td align="left"> Abnormal Ejaculation<sup>b,c</sup> </td> <td>26</td> <td> 1</td> <td> 17 </td> <td>3</td> <td>27</td> <td>3</td> <td>15</td> <td>1</td> </tr> <tr> <td align="left"> Somnolence</td> <td>22 </td> <td> 8</td> <td> 21</td> <td>12</td> <td>20</td> <td>9</td> <td>9</td> <td> 4 </td> </tr> <tr> <td align="left"> Nausea </td> <td> 22</td> <td> 10</td> <td> - </td> <td> - </td> <td> 23 </td> <td> 17 </td> <td> 22 </td> <td> 6 </td> </tr> <tr> <td align="left"> Diarrhea </td> <td> 18</td> <td> 7</td> <td> 15 </td> <td> 9 </td> <td> 12 </td> <td> 9 </td> <td> 9 </td> <td> 8 </td> </tr> <tr> <td align="left"> Insomnia </td> <td> 17</td> <td> 9</td> <td> 10 </td> <td> 8 </td> <td> 20 </td> <td> 11 </td> <td> 9 </td> <td> 4 </td> </tr> <tr> <td align="left"> Dry Mouth</td> <td> 15</td> <td> 8</td> <td>18</td> <td>7</td> <td>13</td> <td>9</td> <td>3</td> <td>2</td> </tr> <tr> <td align="left">Dizziness</td> <td>14</td> <td> 4</td> <td>9</td> <td>5</td> <td>NA</td> <td>NA</td> <td> 7</td> <td>4</td> </tr> <tr> <td align="left">Asthenia </td> <td> 14</td> <td> 9</td> <td>15</td> <td>14</td> <td>15</td> <td>10</td> <td>18</td> <td>7</td> </tr> <tr> <td align="left">Female Genital Disorder<sup>b,d</sup> </td> <td> 10</td> <td>&lt; 1</td> <td> -</td> <td>-</td> <td>7</td> <td>1</td> <td>3</td> <td>0</td> </tr> <tr> <td align="left"> Constipation</td> <td> 10</td> <td>4</td> <td>13</td> <td>5</td> <td>9</td> <td>6</td> <td>5</td> <td>2</td> </tr> <tr> <td align="left"> Tremor</td> <td> 7</td> <td>1</td> <td>7</td> <td>0</td> <td>8</td> <td>2</td> <td>4</td> <td>2</td> </tr> <tr> <td align="left"> Abdominal Pain</td> <td>7</td> <td>4</td> <td>-</td> <td>-</td> <td>6</td> <td>4</td> <td>5</td> <td>4</td> </tr> <tr> <td align="left"> Libido Decreased</td> <td> 7</td> <td>3</td> <td>8</td> <td>&lt;1</td> <td>9</td> <td>4</td> <td/> <td>1</td> </tr> <tr> <td>Sweating </td> <td> 6</td> <td>2</td> <td>10</td> <td>&lt;1</td> <td>7</td> <td>2</td> <td>14</td> <td>3</td> </tr> <tr> <td align="left">Flatulence </td> <td> 6</td> <td>4</td> <td>-</td> <td>-</td> <td>NA</td> <td>NA</td> <td>NA</td> <td>NA</td> </tr> <tr> <td align="left">Abnormal Vision<sup>a</sup> </td> <td> 5</td> <td>1</td> <td>-</td> <td>-</td> <td>3</td> <td>10</td> <td>1</td> <td>9</td> </tr> <tr> <td align="left"> Impotence<sup>b</sup> </td> <td> 5</td> <td> 3</td> <td> 9 </td> <td> 3 </td> <td> 10 </td> <td> 1 </td> <td> 9 </td> <td> 0 </td> </tr> <tr> <td align="left">Back Pain</td> <td>5</td> <td>3</td> <td>-</td> <td>-</td> <td>NA</td> <td>NA</td> <td>4</td> <td>1</td> </tr> <tr> <td align="left">Decreased Appetite</td> <td/> <td>2</td> <td>12</td> <td>5</td> <td>8</td> <td>6</td> <td>1</td> <td>&lt;1</td> </tr> <tr> <td align="left">Dyspepsia</td> <td>NA</td> <td>NA</td> <td>13</td> <td>10</td> <td>NA</td> <td>NA</td> <td>2</td> <td>&lt;1</td> </tr> <tr> <td align="left">Myalgia</td> <td>NA</td> <td>NA</td> <td>-</td> <td>-</td> <td>5</td> <td>3</td> <td>NA</td> <td>NA</td> </tr> <tr> <td align="left">Sinusitis</td> <td>NA</td> <td>NA</td> <td>-</td> <td>-</td> <td>8</td> <td>5</td> <td>NA</td> <td>NA</td> </tr> <tr> <td align="left">Nervousness</td> <td>NA</td> <td>NA</td> <td>-</td> <td>-</td> <td>8</td> <td>7</td> <td>NA</td> <td>NA</td> </tr> <tr> <td align="left">Anxiety</td> <td>NA</td> <td>NA</td> <td>-</td> <td>-</td> <td>5</td> <td>4</td> <td>2</td> <td>1</td> </tr> <tr> <td align="left">Yawn</td> <td/> <td>0</td> <td>-</td> <td>-</td> <td>3</td> <td>0</td> <td>2</td> <td>0</td> </tr> </tbody> </table>

adverse reactions table

<table frame="box" rules="all"> <tbody align="center"> <tr> <td align="left" rowspan="2"> <content styleCode="bold"> </content> <content styleCode="bold"> </content> <content styleCode="bold"/> </td> <td colspan="4"> <content styleCode="bold">% Reporting Adverse Reaction</content> </td> </tr> <tr> <td colspan="2"> <content styleCode="bold">Continuous Dosing</content> </td> <td colspan="2"> <content styleCode="bold">Luteal Phase Dosing</content> </td> </tr> <tr> <td> <content styleCode="bold">PAXIL CR</content> <content styleCode="bold"> (n = 681) </content> </td> <td> <content styleCode="bold">Placebo</content> <content styleCode="bold"> (n = 349)</content> </td> <td> <content styleCode="bold">PAXIL CR</content> <content styleCode="bold"> (n = 246)</content> </td> <td> <content styleCode="bold">Placebo</content> <content styleCode="bold"> (n = 120)</content> </td> </tr> <tr> <td align="left"> Asthenia </td> <td> 17%</td> <td> 6%</td> <td> 15%</td> <td> 4%</td> </tr> <tr> <td align="left">Nausea</td> <td>17%</td> <td>7%</td> <td>18%</td> <td>2%</td> </tr> <tr> <td align="left"> Headache </td> <td> 15%</td> <td>12%</td> <td> NA</td> <td> NA</td> </tr> <tr> <td align="left">Libido Decreased</td> <td>12%</td> <td>5%</td> <td>9%</td> <td>6%</td> </tr> <tr> <td align="left"> Somnolence </td> <td> 9%</td> <td>2%</td> <td>3%</td> <td>&lt;1%</td> </tr> <tr> <td align="left">Female Genital Disorders<sup>c</sup> </td> <td>8%</td> <td>1%</td> <td>2%</td> <td>0%</td> </tr> <tr> <td align="left"> Insomnia </td> <td> 8%</td> <td>2%</td> <td>7%</td> <td>3%</td> </tr> <tr> <td align="left">Sweating</td> <td>7%</td> <td>&lt;1%</td> <td>6%</td> <td>&lt;1%</td> </tr> <tr> <td align="left"> Dizziness </td> <td> 7%</td> <td>3%</td> <td>6%</td> <td> 3%</td> </tr> <tr> <td align="left">Diarrhea</td> <td>6%</td> <td>2%</td> <td>6%</td> <td>3%</td> </tr> <tr> <td align="left">Infection</td> <td>6%</td> <td>4%</td> <td>NA</td> <td>NA</td> </tr> <tr> <td align="left">Constipation</td> <td>5%</td> <td>1%</td> <td>2%</td> <td>&lt;1%</td> </tr> <tr> <td align="left"> Tremor </td> <td>4%</td> <td>&lt;1%</td> <td>5%</td> <td>0%</td> </tr> </tbody> </table>

adverse reactions table

<table frame="box" rules="all"> <tbody align="center"> <tr> <td> <content styleCode="bold"> </content> </td> <td colspan="2"> <content styleCode="bold">Studies 1 and 2 (MDD)</content> </td> <td colspan="2"> <content styleCode="bold">Studies 4, 5 and 6 (PD)</content> </td> <td colspan="2"> <content styleCode="bold">Study 7 (SAD) </content> </td> <td colspan="2"> <content styleCode="bold">Studies 8, and 9 and 10 (Continuous Dosing) (PMDD)</content> </td> <td colspan="2"> <content styleCode="bold">Study 11 (Luteal Phase Dosing) (PMDD)</content> </td> </tr> <tr> <td> <content styleCode="bold"> </content> </td> <td> <content styleCode="bold">PAXIL CR</content> </td> <td> <content styleCode="bold">Placebo</content> </td> <td> <content styleCode="bold">PAXIL CR</content> </td> <td> <content styleCode="bold">Placebo</content> </td> <td> <content styleCode="bold">PAXIL CR</content> </td> <td> <content styleCode="bold">Placebo</content> </td> <td> <content styleCode="bold">PAXIL CR</content> </td> <td> <content styleCode="bold">Placebo</content> </td> <td> <content styleCode="bold">PAXIL CR</content> </td> <td> <content styleCode="bold">Placebo</content> </td> </tr> <tr> <td align="left"> <content styleCode="bold">n (males)</content> </td> <td> <content styleCode="bold">78</content> </td> <td> <content styleCode="bold">78</content> </td> <td> <content styleCode="bold">162</content> </td> <td> <content styleCode="bold">194</content> </td> <td> <content styleCode="bold">88</content> </td> <td> <content styleCode="bold">97</content> </td> <td> <content styleCode="bold">NA</content> </td> <td> <content styleCode="bold">NA</content> </td> <td> <content styleCode="bold">NA</content> <content styleCode="bold"/> </td> <td> <content styleCode="bold">NA</content> <content styleCode="bold"/> </td> </tr> <tr> <td align="left">Abnormal ejaculation</td> <td>26%</td> <td>1%</td> <td>27</td> <td>27%</td> <td>3%</td> <td>15%</td> <td>1%</td> <td>NA</td> <td>NA</td> <td>NA</td> </tr> <tr> <td align="left"> Decreased Libido </td> <td>10%</td> <td>5%</td> <td>9%</td> <td>6%</td> <td>13%</td> <td>1%</td> <td> NA </td> <td> NA </td> <td> NA </td> <td> NA </td> </tr> <tr> <td align="left"> Impotence </td> <td> 5%</td> <td>3%</td> <td>10%</td> <td>1%</td> <td>9%</td> <td>0%</td> <td> NA </td> <td> NA </td> <td> NA </td> <td> NA </td> </tr> <tr> <td align="left"> <content styleCode="bold">n (females)</content> </td> <td> <content styleCode="bold">134</content> </td> <td> <content styleCode="bold">133</content> </td> <td> <content styleCode="bold">282</content> </td> <td> <content styleCode="bold">251</content> </td> <td> <content styleCode="bold">98</content> </td> <td> <content styleCode="bold">87</content> </td> <td> <content styleCode="bold">681</content> </td> <td> <content styleCode="bold">349</content> </td> <td> <content styleCode="bold">246</content> </td> <td> <content styleCode="bold">120</content> </td> </tr> <tr> <td align="left">Orgasmic Disturbance</td> <td>10%</td> <td>&lt;1%</td> <td>7%</td> <td>1%</td> <td>3%</td> <td>0%</td> <td>8%</td> <td>1%</td> <td>2%</td> <td>0%</td> </tr> <tr> <td align="left"> Decreased Libido </td> <td> 4%</td> <td>2%</td> <td>8%</td> <td>2%</td> <td>4%</td> <td>1%</td> <td>12%</td> <td>5%</td> <td>9%</td> <td>6%</td> </tr> </tbody> </table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.